nach oben

Erschienen in:

29.10.2018 | Original Article

Fractionated stereotactic radiation therapy for adrenal metastases: contributing to local tumor control with low toxicity

verfasst von: Kim Burjakow, Prof. Dr. Rainer Fietkau, Dr. Florian Putz, Dr. Nils Achterberg, Dr. Sebastian Lettmaier, Dr. Stefan Knippen

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To report on the Erlangen (UK-Er) experience with linear accelerator stereotactic body radiation therapy (LINAC SBRT) for adrenal metastasis from various primary tumors.

Materials and methods

33 patients were treated. Primary sites included lung (n = 19), melanoma (n = 8), colorectal (n = 2), hepatocellular (n = 1), esophageal (n = 2), and breast cancer (n = 1). 14 patients were treated palliatively, 19 patients were treated with local curative intent.

Radiation treatment

Treatment planning was done based on an exhale, mid-ventilation, and inspiration CT series. Further planning CTs were done to check for the correctness of the breathing pattern. Irradiation was performed using a NOVALIS (Varian, Palo Alto, CA, USA; Brainlab AG, München, Germany) linear accelerator. The isocenter was verified before each treatment session using the BrainLab ExacTrac® (Brainlab AG, München, Germany) system to minimize setup errors. Dose was prescribed to the planning target volume (PTV) surrounding 90% isodose.

Follow-up

Depending on their overall performance status and prognosis, patients received clinical check-ups and radiological imaging. Median follow-up was 11 months.

Statistical analysis

IBM SPSS v. 24 was used for univariate analysis using Kaplan–Meier curves, nonparametric Kruskal–Wallis test, and the chi-square test for frequency distributions. Toxicity was graded according to NCI CTCAE v4.0. Depending on radiologic imaging, patients were classified as stable, regression, and progression.

Results

Median survival was 11 months, median PFS was 5 months. Median local failure-free survival was 21 months. Patients who were treated with curative intent showed a better survival curve (p < 0.0001) and PFS (p = 0.004). BED ranged from 42 to 108.8 Gy, median BED was 67.2 Gy. Three BED groups were formed. Overall survival curves differed significantly (p = 0.046), favoring the high-dose group. 21 patients were free from any adverse events or discomfort. In 7 cases, a grade I toxicity was noted.

Kung AWC, Pun KK, Lam K, Wang C, Leung CY (1990) Addisonian Crisis as Presenting Feature in Malignancies. Cancer 65(1):177–179. https://doi.org/10.1002/1097-0142(19900101)65:1 CrossRefPubMed

Lam KY, Lo CY (2002) Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol 56(1):95–101. https://doi.org/10.1046/j.0300-0664.2001.01435.x CrossRef

Twomey P, Montgomery C, Clark O (1982) Successful treatment of adrenal metastases from large-cell carcinoma of the lung. J Am Med Assoc 248(5):581–583. https://doi.org/10.1001/jama.248.5.581 CrossRef

Lo CY, vanHeerden JA, Soreide JA, Grant CS, Thompson GB, Lloyd RV, Harmsen WS (1996) Adrenalectomy for metastatic disease to the adrenal glands. Brit J Surg 83(4):528–531. https://doi.org/10.1002/bjs.1800830432 CrossRefPubMed

Mohnike K, Neumann K, Hass P, Seidensticker M, Seidensticker R, Pech M, Klose S, Streitparth T, Garlipp B, Benckert C, Wendler JJ, Liehr UB, Schostak M, Goppner D, Gademann G, Ricke J (2017) Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy : Efficacy and outcome. Strahlenther Onkol 193(8):612–619. https://doi.org/10.1007/s00066-017-1120-2 CrossRefPubMed

Soffen EM, Solin LJ, Rubenstein JH, Hanks GE (1990) Palliative radiotherapy for symptomatic adrenal metastases. Cancer 65(6):1318–1320CrossRefPubMed

Short S, Chaturvedi A, Leslie MD (1996) Palliation of symptomatic adrenal gland metastases by radiotherapy. Clin Oncol 8(6):387–389CrossRef

Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, Watanabe Y, Shinohara N, Ishikawa M, Shirato H (2008) Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol 87(3):418–424. https://doi.org/10.1016/j.radonc.2008.03.013 CrossRefPubMed

Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL, Brunner TB (2017) Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlenther Onkol 193(6):433–443. https://doi.org/10.1007/s00066-017-1099-8 CrossRefPubMed

10.

Brunner TB, Nestle U, Adebahr S, Gkika E, Wiehle R, Baltas D, Grosu AL (2016) Simultaneous integrated protection : A new concept for high-precision radiation therapy. Strahlenther Onkol 192(12):886–894. https://doi.org/10.1007/s00066-016-1057-x CrossRefPubMedPubMedCentral

11.

De Ruysscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Geraedts W, Baumert BG, Lambin P (1555) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 201(2):1547. https://doi.org/10.1097/JTO.0b013e318262caf6 CrossRef

12.

Gomez DR, Blumenschein GR Jr., Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672–1682. https://doi.org/10.1016/S1470-2045(16)30532-0 CrossRefPubMedPubMedCentral

13.

Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, Sauer O, Deutschen Gesellschaft fur R (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190(1):26–33. https://doi.org/10.1007/s00066-013-0450-y CrossRefPubMed

14.

Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, Milano MT (2009) Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 75(1):71–75. https://doi.org/10.1016/j.ijrobp.2008.10.079 CrossRefPubMed

15.

Holy R, Piroth M, Pinkawa M, Eble MJ (2011) Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 187(4):245–251. https://doi.org/10.1007/s00066-011-2192-z CrossRefPubMed

16.

Ahmed KA, Barney BM, Macdonald OK, Miller RC, Garces YI, Laack NN, Haddock MG, Foote RL, Olivier KR (2013) Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol 36(5):509–513. https://doi.org/10.1097/COC.0b013e3182569189 CrossRefPubMed

17.

Casamassima F, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I, Bonucci I, Agresti B, Simontacchi G, Doro R (2012) Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys 82(2):919–923. https://doi.org/10.1016/j.ijrobp.2010.11.060 CrossRefPubMed

18.

Desai A, Rai H, Haas J, Witten M, Blacksburg S, Schneider JG (2015) A retrospective review of Cyberknife stereotactic body radiotherapy for adrenal tumors (primary and metastatic): Winthrop university hospital experience. Front Oncol 5:185. https://doi.org/10.3389/fonc.2015.00185 CrossRefPubMedPubMedCentral

19.

Haidenberger A, Heidorn SC, Kremer N, Muacevic A, Furweger C (2017) Robotic radiosurgery for adrenal gland metastases. Cureus 9(3):e1120. https://doi.org/10.7759/cureus.1120 CrossRefPubMedPubMedCentral

20.

Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY (2017) Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol 7(3):e195–e203. https://doi.org/10.1016/j.prro.2016.09.005 CrossRefPubMed

Titel: Fractionated stereotactic radiation therapy for adrenal metastases: contributing to local tumor control with low toxicity
verfasst von: Kim Burjakow
Prof. Dr. Rainer Fietkau
Dr. Florian Putz
Dr. Nils Achterberg
Dr. Sebastian Lettmaier
Dr. Stefan Knippen
Publikationsdatum: 29.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2019
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1390-3

Springer Medizin

Fractionated stereotactic radiation therapy for adrenal metastases: contributing to local tumor control with low toxicity